1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2020, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.
Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 5, 1, 21 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionChemotherapy Induced Peripheral Neuropathy - Overview
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment
Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development
Chemotherapy Induced Peripheral Neuropathy - Drug Profiles
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products
Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2020
- Chemotherapy Induced Peripheral Neuropathy - Pipeline by Algo Therapeutix SAS, H2 2020
- Chemotherapy Induced Peripheral Neuropathy - Pipeline by Annji Pharmaceutical Co Ltd, H2 2020
- Chemotherapy Induced Peripheral Neuropathy - Pipeline by Apexian Pharmaceuticals Inc, H2 2020
- Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aphios Corp, H2 2020
- Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aptinyx Inc, H2 2020
- Chemotherapy Induced Peripheral Neuropathy - Pipeline by Asahi Kasei Pharma Corp, H2 2020
- Chemotherapy Induced Peripheral Neuropathy - Pipeline by Bristol-Myers Squibb Co, H2 2020
- Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2020
- Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Molecule Types, H2 2020
- Number of Products by Stage and Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Achelios Therapeutics Inc
- Algo Therapeutix SAS
- Annji Pharmaceutical Co Ltd
- Apexian Pharmaceuticals Inc
- Aphios Corp
- Aptinyx Inc
- Asahi Kasei Pharma Corp
- Bristol-Myers Squibb Co
- Candel Therapeutics
- Disarm Therapeutics Inc
- Emerald Bioscience Inc
- Exodos Life Sciences Limited Partnership
- Immune Pharmaceuticals Inc
- KannaLife Sciences Inc
- Kineta Inc
- Kyorin Pharmaceutical Co Ltd
- MAKScientific LLC
- Medifron DBT Co Ltd
- Metys Pharmaceuticals AG
- Mundipharma International Ltd
- NeurExo Sciences LLC
- Osmol Therapeutucs Inc
- PharmatrophiX Inc
- PledPharma AB
- Regulonix LLC
- Senzer Ltd
- SiteOne Therapeutics Inc
- Sonnet BioTherapeutics Holdings Inc
- Sova Pharmaceuticals Inc
- Stealth BioTherapeutics Corp
- Toray Industries Inc
- Trevena Inc
- WEX Pharmaceuticals Inc
- Winsantor Inc
- YD Life Science Co
